Phase II
Pelareorep and FOLFIRI/B combination shows superior OS & PFS data in KRAS mutant colorectal cancer compared to historical data
Sinntaxis announces today that it has entered into an option agreement with Acturum for an exclusive license to drug candidate AZD2066 for the development of a potentially pioneering treatment helping stroke survivors recover brain function.
In May the FDA placed a hold on the trial and IND for CTX001, an investigational gene editing treatment, citing concerns over questions that had not been addressed in the IND.
A post-hoc analysis of a Phase II sickle cell disease study showed that patients treated with crizanlizumab significantly reduced occurrences of vaso-occlusive crisis, a serious disease complication that can lead to organ failure.
Retrophin, Inc. today announced that it will present new data examining the long-term effects of sparsentan in focal segmental glomerulosclerosis (FSGS), at the American Society of Nephrology (ASN) Kidney Week 2018.
Opioids have shown tremendous efficacy in pain management. At the same time, the dangers of the addiction to the medication have become well-known in recent years as an epidemic has swept across the United States.
KOL event to be held ahead of expected data release with elafibranor in PBC by end of 2018 (Phase 2) and in NASH end of 2019 (Phase 3)
PTC Therapeutics announced interim data from Part 1 of its open-label clinical trials, FIREFISH and SUNFISH, of risdiplam for Type 1, 2 and 3 spinal muscular atrophy in collaboration with Genentech.
Yesterday, top-line data from Bionomics Limited revealed details of the biopharmaceutical company’s Phase II clinical trial of BNC210 in regards to patients with post traumatic stress disorder.
Trial did not meet primary endpoint of decrease in PTSD symptoms as measured by CAPS-5 at 12 weeks
PRESS RELEASES